NCT03922061View on ClinicalTrials.gov

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

July 18, 2019

Study Completion Date

June 4, 2020

Conditions
Polio
Interventions
BIOLOGICAL

dmLT

double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)

BIOLOGICAL

fIPV

fractional-dose inactived polio vaccine

Trial Locations (1)

05405

University of Vermont, Burlington

All Listed Sponsors
lead

University of Vermont

OTHER

NCT03922061 - Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant | Biotech Hunter | Biotech Hunter